שווי מתואם לחוב ומזומנים Biofrontera Inc. (BFRI)

The market trend for Biofrontera Inc. (BFRI) illustrated on this price chart demonstrates an enterprise value of 15.04. Business growth is driven by Ameluz system sales in the US, the expansion of the sales department, and improved insurance coverage. Meanwhile, the company is engaged in a fierce battle with manufacturers of affordable alternatives. This dermatological player is seeking approval for the treatment of extensive skin areas while developing specialized pharmaceuticals.

Sales of photodynamic therapy systems and the Ameluz drug across US medical centers form the asset base of Biofrontera Inc. (BFRI), the value of which is reflected in this metric. The enterprise value assessment sums the market capitalization with net debt, allowing the investor to determine the actual buyout price of the company, accounting for all liabilities and cash reserves to analyze financial stability.